Corcept Therapeutics Incorporated (CORT) Earnings History
Annual and quarterly earnings data from 2003 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 98.3% | 5.9% | 13.1% |
| 2024 | 98.4% | 20.3% | 20.7% |
| 2023 | 98.7% | 22.2% | 22.0% |
| 2022 | 98.7% | 28.0% | 25.2% |
| 2021 | 98.6% | 34.0% | 30.7% |
Download Data
Export CORT earnings history in CSV or JSON format
Free sign-in required to download data
Corcept Therapeutics Incorporated (CORT) Earnings Overview
As of March 1, 2026, Corcept Therapeutics Incorporated (CORT) reported trailing twelve-month net income of $99M, reflecting -0.3% year-over-year growth. The company earned $0.83 per diluted share over the past four quarters, with a net profit margin of 0.1%.
Looking at the long-term picture, CORT's 5-year EPS compound annual growth rate (CAGR) stands at -0.7%, signaling declining earnings. The company achieved its highest annual net income of $140M in fiscal 2024.
Corcept Therapeutics Incorporated maintains positive profitability with a gross margin of 1.0%, operating margin of 0.1%, and net margin of 0.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including AGIO (-$401M net income, -7.6% margin), VRTX ($3.68B net income, 0.3% margin), ASND (-$228M net income, -0.3% margin), CORT has outperformed on profitability metrics. Compare CORT vs AGIO →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
23 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $100M | -28.7% | $45M | $0.82 | 13.1% | 5.9% |
| 2024 | $140M | +31.6% | $137M | $1.23 | 20.7% | 20.3% |
| 2023 | $106M | +4.7% | $107M | $0.94 | 22.0% | 22.2% |
| 2022 | $101M | -9.9% | $113M | $0.87 | 25.2% | 28.0% |
| 2021 | $113M | +6.1% | $124M | $0.89 | 30.7% | 34.0% |
| 2020 | $106M | +12.6% | $128M | $0.85 | 30.0% | 36.2% |
| 2019 | $94M | +24.9% | $112M | $0.77 | 30.7% | 36.4% |
| 2018 | $75M | -41.6% | $89M | $0.60 | 30.0% | 35.6% |
| 2017 | $129M | +1486.3% | $53M | $1.04 | 81.1% | 33.2% |
| 2016 | $8M | +227.0% | $10M | $0.07 | 10.0% | 12.5% |
See CORT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CORT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CORT vs AGIO
See how CORT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CORT growing earnings?
CORT EPS of $0.83 reflects slowing growth at -0.3%, below the 5-year CAGR of -0.7%. TTM net income is $99M. Expansion rate has moderated.
What are CORT's profit margins?
Corcept Therapeutics Incorporated net margin is +0.1%, with operating margin at +0.1%. Below-average margins reflect competitive or cost pressures.
How consistent are CORT's earnings?
CORT earnings data spans 2003-2025. The current earnings trend is -0.3% YoY. Historical data enables comparison across business cycles.